Innate Pharma SA (IPH.PA)

IPH.PA on Paris Stock Exchange

8.20EUR
19 Dec 2014
Price Change (% chg)

€-0.26 (-3.07%)
Prev Close
€8.46
Open
€8.48
Day's High
€8.57
Day's Low
€8.15
Volume
447,374
Avg. Vol
--
52-wk High
--
52-wk Low
--

IPH.PA

Chart for IPH.PA

About

Innate Pharma SA is a France-based biopharmaceutical Company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of... (more)

Overall

Beta: 0.69
Market Cap (Mil.): €434.32
Shares Outstanding (Mil.): 52.97
Dividend: --
Yield (%): --

Financials

  IPH.PA Industry Sector
P/E (TTM): -- 179.07 38.47
EPS (TTM): -0.21 -- --
ROI: -16.34 -0.72 18.25
ROE: -18.04 -1.88 19.13
Search Stocks

BRIEF-Innate Pharma opens first phase II trial with IPH2201

* First phase II trial with IPH2201 opens in head and neck cancer

19 Dec 2014

BRIEF-Innate pharma closes patient enrollment in phase I trail

* Innate Pharma enrollment closes to new patients in phase I trial investigating Lirilumab in combination with Ipilimumab Source text for Eikon: Further company coverage: (Gdynia Newsroom)

12 Dec 2014

BRIEF-Innate Pharma reports Q3 revenue loss

* Q3 2014 revenue loss of 55,000 euros vs revenue of 2.3 million euros last year

09 Dec 2014

U.S. OKs genetically modified potato with lower cancer risk

(This Nov. 7 story has been corrected to say that Innate is not the first GM potato to be approved by USDA)

10 Nov 2014

BRIEF-Innate Pharma announces new sets of preclinical data on its BTG-ADC technology

* Presents at World ADC Summit two posters showing new sets of preclinical data on its new, site-specific conjugation technology (BTG-ADC)

28 Oct 2014

BUZZ-Innate Pharma: Citi lauds French biotech firm's cancer work

** Shares in French biotechnology company Innate Pharma jump 8 pct as Citi initiates with a "buy" recommendation and 10 euros/share PT.

09 Oct 2014

BRIEF-Innate Pharma announces Phase I trial of lirilumab in combination with elotuzumab

* Initiates Phase I clinical trial of lirilumab in combination with elotuzumab

01 Oct 2014

BRIEF-Innate Pharma H1 net loss rises to 9 million euros

* H1 net loss 9 million euros versus loss of eur 2.3 million in H1 2013

17 Sep 2014

BRIEF-Innate Pharma appoints Pierre Dodion chief medical officer

* Appoints Pierre Dodion chief medical officer Source text for Eikon: Further company coverage: (Gdynia Newsroom: +48 58 698 39 20; Gdynia.newsroom@thomsonreuters.com)

16 Sep 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Directors Deals Ltd.
$12.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks